Paul Fehlner is a co-founder and President/CEO of reVision Therapeutics, Inc., which was created to advance low price innovative medicines through open innovation principles. Concurrently, he is Chief LegalOfficer at Axcella Health, a clinical stage company in Cambridge, Massachusetts and a Principal of Life Sciences Innovation LLC, a consulting company that advises on products and technologies and provides BD&L support in life sciences. Previously, Dr. Fehlner was Head of Intellectual Property for Novartis Pharma in Basel, Switzerland, leading a team of over 120 colleagues in 5 countries to obtain, maintain, and enforce IP rights for the company in collaboration with global and local stakeholders. Dr. Fehlner joined Novartis in 2008 from the international law firm Baker Botts, where he led the firm’s life sciences IP practice. He was an associate and partner at Darby & Darby, Biotechnology Counsel for Rhône-Poulenc Rorer, an associateat Klauber & Jackson, and began his career in 1990 at Pennie & Edmonds. Hehas a JD from Fordham, a PhD from Rockefeller University (Lois P Markey Fellow), and a BS from Haverford College (high honors; Phi Beta Kappa).
